Series K, Number 7
Injectables and Implants

CONTENTS

Home (Key Points)

New Implants Can Expand Access
Table 1. Comparing Implants
Table 2. Continuation Rates for New Implants
Table 3. Estimated Worldwide Use of Implants

Box: Which New Implant to Introduce?

Spotlight: From Norplant to Jadelle: Smooth Transition in a Dominican Republic Clinic

Preparing to Offer New Implants

Spotlight: Training Nurses Increases Implant Use in Ghana

Box: Information and Communication Technology Supports Implant Programs

Meeting Demand for New Implants Requires Supply and Access
Table 4. Key Resources for Program Managers and Providers of Implants

Bibliography

Credits

• Box: What Clients Should Know About Insertion and Removal
• INFO Reports: “Implants: Tools for Providers”

• Table 1: Comparing Implants
• Table 4: Key Resources for Program Managers and Providers of Implants

Order this report
Download PDF or PowerPoint
E-mail this page
See Companion INFO Report
"Implants: Tools for Providers"
See more Population Reports
See Implants Toolkit

Bibliography

An asterisk (*) denotes an item that was particularly useful in the preparation of this issue of Population Reports. The links in this bibliography were up-to-date as of publication.

1. ACQUIRE PROJECT UGANDA. Projections of Contraceptive Use for Uganda. [unpublished paper]. 2005. 16 p.

2. AGUILAR, Z., DUARTE, T., BRATT, J., BRAMBILA, C., and FOREIT, J. Willingness to pay for reproductive health services among APROFAM clients, Guatemala. Washington, D.C., Population Council, Frontiers in Reproductive Health, Dec. 2001. 21 p.

3. ARMAND, F. The sustainability challenge: Identifying appropriate financing models for social marketing programs. Washington, D.C., Commercial Market Strategies Project, Oct. 2003. (Occasional Paper Series) 42 p.

4. ARMANTO, K. (Bayer Schering Pharma) [Jadelle training materials available from Bayer] Personal communication, Sep. 11, 2007.

5. ARMANTO, K. (Bayer Schering Pharma) [Norplant discontinuation and pricing of Jadelle] Personal communication, Jul. 2, 2007.

6. BAYER SCHERING PHARMA. [Manufacturing costs of Jadelle] Personal communication, Aug. 24, 2007.

7. BEST, K. Training involves many factors. Network, 19, No. 1. Family Health International, Fall 1998.

8. BLUMENTHAL, P., GAFFIKIN, L., AFFANDI, B., BONGIOVANNI, A., ANIMONA, R., GLEW, G., and MCGRATH, J. Comparative assessment of Norplant® implants removal techniques: Indonesia. Baltimore, JHPIEGO, Mar. 1996. (JHPIEGO Technical Report No. FCA-22) 9 p.

9. BLUMENTHAL, P.D., GAFFIKIN, L., AFFANDI, B., BONGIOVANNI, A., MCGRATH, J., and GLEW, G. Training for Norplant implant removal: Assessment of learning curves and competency. Obstetrics and Gynecology 89(2): 174-178. Feb. 1997.

10. BONGIOVANNI, A. and GAFFIKIN, L. Indonesia field assessment: Subdermal implant training model. Baltimore, JHPIEGO, Jan. 1996. (JHPIEGO Technical Report No. FCA-18) 9 p.

11. BRACHE, V. (Biomedical Research Department, PROFAMILIA) [The PROFAMILIA Clinic's transition to Jadelle] Personal communication, Jun. 4, 2007.

*12. BRACHE, V., FAUNDES, A., ALVAREZ, F., and GARCIA, A.G. Transition from Norplant to Jadelle in a clinic with extensive experience providing contraceptive implants. Contraception 73(4): 364-367. Apr. 2006.

13. BROMHAM, D.R., DAVEY, A., GAFFIKIN, L., and AJELLO, C.A. Materials, methods and results of the Norplant training program. Advances in Contraception 11(3): 255-262. Sep. 1995.

14. CENTRAL STATISTICAL AGENCY [ETHIOPIA] and ORC MACRO. Ethiopia Demographic and Health Survey 2005. Addis Ababa, Ethiopia and Calverton, Maryland, Central Statistical Agency and ORC Macro, 410 p.

*15. CHAOVISITSAREE, S., PIYAMONGKOL, W., PONGSATHA, S., MORAKOTE, N., NOIUM, S., and SOONTHORNLIMSIRI, N. One year study of Implanon on the adverse events and discontinuation. Journal of the Medical Association of Thailand 88(3): 314-317. Mar. 2005.

*16. CHIKAMATA, D.M. and MILLER, S. Health services at the clinic level and implantable contraceptives for women. Contraception 65(1): 97-106. Jan. 2002.

*17. CRAVIOTO, M.D.C., ALVARADO, G., CANTO-DE-CETINA, T., BASSOL, S., OROPEZA, G., SANTOS-YUNG, R., VALENCIA, J., PALMA, Y., FUZIWARA, J.L., NAVARRETE, T., GARZA-FLORES, J., and PEREZ-PALACIOS, G. A multicenter comparative study on the efficacy, safety, and acceptability of the contraceptive subdermal implants Norplant and Norplant-II. Contraception 55(6): 359-367. Jun. 1997.

18. CROXATTO, H.B. Progestin implants. Steroids 65(10-11): 681-685. Oct.-Nov. 2000.

*19. CROXATTO, H.B. Mechanisms that explain the contraceptive action of progestin implants for women. Contraception 65(1): 21-27. Jan. 2002.

*20. DELIVER. Kenya: Final country report. Arlington, Virginia, U.S. Agency for International Development (USAID), 2007. 34 p.

*21. DOUCOURE, A., TANDIA, D., SANGARE, M., and KATZ, L. Programmatic evaluation of Norplant introduction in Mali. Bamako, Mali, Division Sante Familiale et Communautaire, Sep. 1995. 47 p.

22. EL ZANATY, F., NAWAR, L., and HAMED, R. An assessment of selected sub-systems of the Egyptian Norplant program. New York, Population Council, Jul. 2001. 34 p.

23. ENGENDERHEALTH. Improving access and quality of clinical family planning services in the public and private sectors in Ghana: End of project report. Accra, Ghana, EngenderHealth, 2004. 37 p.

24. FAMILY PLANNING LOGISTICS MANAGEMENT/JOHN SNOW INC. (JSI). Programs that deliver. Logistics' contributions to better health in developing countries. Arlington, Virginia, U.S. Agency for International Development (USAID), JSI Family Planning Logistics Management/John Snow Inc., 2000. 117 p.

*25. FAN, H., HAN, L., JIANG, J., WU, M., and CHEN, B. A multicenter comparative clinical study of sino-levonorgestrel-releasing impants-No. I and No. II with Norplant. Journal of Reproduction and Contraception 15(2): 101-107. 2004.

*26. FANG, K., GUAN, Y., and FAN, H. [A multicentre study of 2 types of sino-implant (expanded application) (two year follow-up)]. Chinese Journal of Family Planning 6(1): 11-14, 47. 1998.

*27. FISHER, A.A., PRIHARTONO, J., TULADHAR, J., and HOESNI, R.H. An assessment of Norplant removal in Indonesia. Studies in Family Planning 28(4): 308-316. Dec. 1997.

*28. FLORES, J.B., BALDERAS, M.L., BONILLA, M.C., and VAZQUEZ-ESTRADA, L. Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant. International Journal of Gynaecology and Obstetrics 90(3): 228-233. Sep. 2005.

*29. FOREIT, J.R. and FOREIT, K.G. The reliability and validity of willingness to pay surveys for reproductive health pricing decisions in developing countries. Health Policy 63(1): 37-47. Jan. 2003.

30. GHANA STATISTICAL SERVICE (GSS), HEALTH RESEARCH UNIT OF THE MINISTRY OF HEALTH, and ORC MACRO. Ghana service provision assessment survey 2002. Calverton, Maryland, Ghana Statistical Service and ORC Macro, 2003. 397 p.

31. GLASIER, A. Implantable contraceptives for women: Effectiveness, discontinuation rates, return of fertility, and outcome of pregnancies. Contraception 65(1): 29-37. Jan. 2002.

*32. GU, S., SIVIN, I., DU, M., ZHANG, L., YING, L., MENG, F., WU, S., WANG, P., GAO, Y., HE, X., and ET AL. Effectiveness of Norplant implants through seven years: a large-scale study in China. Contraception 52(2): 99-103. Aug. 1995.

*33. HALL, P. What has been achieved, what have been the constraints and what are the future priorities for pharmaceutical product-related R&D to the reproductive health needs of developing countries? Commission on Intellectual Property Rights, Innovation and Public Health, 2006. 63 p.

34. HALL, P. [Potential for more generic production of implants] Personal communication, Jun. 22, 2007.

35. HALL, P.E., OEHLER, J., WOO, P., ZARDO, H., CHINERY, L., SINGH, J.S., JOOSEERY, S.H., and ESSAH, N.M. A study of the capability of manufacturers of generic hormonal contraceptives in lower- and middle-income countries. Contraception 75(4): 311-317. Apr. 2007.

36. HARDEE, K., BALOGH, S., and VILLINSKI, M.T. Three countries' experience with Norplant introduction. Health Policy and Planning 12(3): 199-213. Sep. 1997.

*37. HARDEE, K., BARKAT E, K., KAMAL, G.M., RAHMAN, A.P.M.S., and MCMAHAN, J. Contraceptive implant users and their access to removal services in Bangladesh. International Family Planning Perspectives 20(2): 59-65. Jun. 1994.

38. HARRISON, P.F. and ROSENFIELD, A. Research, introduction, and use: Advancing from Norplant. Contraception 58(6): 323-334. Dec. 1998.

39. HEALTH SERVICES AND SYSTEMS PROGRAM (ZAMBIA). Reproductive health. 2006. 15 p.

40. HICKEY, M. and D'ARCANGUES, C. Vaginal bleeding disturbances and implantable contraceptives. Contraception 65(1): 75-84. Jan. 2002.

41. HONG, R. and FRONCZAK, N. Ghana trend analysis for family planning services 1993, 1996, 2002. Calverton, Maryland, ORC Macro, 2005. 50 p.

*42. HUBACHER, D., KIMANI, J., STEINER, M.J., SOLOMON, M., and NDUGGA, M.B. Contraceptive implants in Kenya: Current status and future prospects. Contraception 75(6): 468-473. Jun. 2007.

43. HULL, T.H. The challenge of contraceptive implant removals in East Nusa Tenggara, Indonesia. International Family Planning Perspectives 24(4): 176-179, 205. Dec. 1998.

44. INTERNATIONAL PLANNED PARENTHOOD FEDERATION (IPPF) INTERNATIONAL MEDICAL ADVISORY PANEL (IMAP). Statement on hormonal methods of contraception. London, IPPF, May 2002. 19 p.

45. INTERNATIONAL SCIENCE AND TECHNOLOGY INSTITUTE INC. Health, population and nutrition projects. International Science and Technology Institute Inc., 2006.

46. ISLEY, M.M. and EDELMAN, A. Contraceptive implants: An overview and update. Obstetrics and Gynecology Clinics of North America 34(1): 73-90, ix. Mar. 2007.

*47. JACOBSTEIN, R. and PILE, J.M. Hormonal implants: New, improved, and potentially popular ACQUIRE Technical Update, New York, The ACQUIRE Project/EngenderHealth, 2007. 2 p.

48. JAIN, A., TAGOE, G., TETTEH, C., and WOHLFAHRT, D. A review of EngenderHealth-supported activities in Ghana. New York, EngenderHealth, 2003. 66 p.

49. JANOWITZ B, KANCHANASINITH K, AUAMKUL N, AMORNWICHET P, SOONTHORNDHADA K, and HANENBERG R. Introducing the contraceptive implant in Thailand: Impact on method use and costs. International Family Planning Perspectives 20(4): 131-136. Dec. 1994.

50. JOHN SNOW INC./DELIVER. PipeLine user's guide. Arlington, Virginia, John Snow Inc./DELIVER, U.S. Agency for International Development (USAID), 2004. 120 p.

51. KANLISI, N. (EngenderHealth) [EngenderHealth's efforts to train providers in implants in Ghana] Personal communication, Aug. 3, 2007.

52. KERRIGAN, M. and GAFFIKIN, L. The effect of Norplant® implants training on increasing access to family planning services: The Senegal and Mali experiences. Baltimore, JHPIEGO, Aug. 1996. (JHPIEGO Technical Report No. FCA-24) 28 p.

53. KIRIWAT, O., PATANAYINDEE, A., KOETSAWANG, S., KORVER, T., and BENNINK, H.J. A 4-year pilot study on the efficacy and safety of Implanon, a single-rod hormonal contraceptive implant, in healthy women in Thailand. European Journal of Contraception and Reproductive Health Care 3(2): 85-91. Jun. 1998.

54. KOVALEVSKY, G. and BARNHART, K. Norplant and other implantable contraceptives. Clinical Obstetrics and Gynecology 44(1): 92-100. Mar. 2001.

55. LADIPO, O.A. and AKINSO, S.A. Contraceptive implants. African Journal of Reproductive Health 9(1): 16-23. Apr. 2005.

56. LANDE, R. and RICHEY, C. Expanding Services for Injectables. Population Reports, Series K, No. 6. Baltimore, INFO Project, Johns Hopkins Bloomberg School of Public Health, Dec. 2006.

*57. LIU, X., MAO, J., CHEN, X., WANG, Z., JIN, Y., WU, X., LI, H., ZHANG, J., ZHU, H., and SU, Z. The safety of Sino-implant -- 3-year clinical observation. Reproduction and Contraception 10(4): 234-241. 1999.

58. LU, E. (JHPIEGO) [The U-technique for inserting implants] Personal communication, Aug. 16, 2007.

59. LU, E. (JHPIEGO) [Use of ICT for training in providing contraceptives] Personal communication, Jul. 18, 2007.

60. MAURICE, J. Contraceptive implants come of age. Progress in Reproductive Health Research [Newsletter], No. 61, Geneva. UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), 2003.

61. MEIRIK, O., FRASER, I.S., and D'ARCANGUES, C. Implantable contraceptives for women. Human Reproduction Update 9(1): 49-59. Jan.-Feb. 2003.

*62. MILLER, K., MILLER, R., ASKEW, I., HORN, M.C., and NDHLOVU, L. Clinic-based family planning and reproductive health services in Africa: Findings from situation analysis studies. New York, The Population Council, 1998. 255 p. (Available: http://www.popcouncil.org/pdfs/Cbfp.pdf)

63. MINISTRY OF HEALTH AND POPULATION, EL-ZANATY ASSOCIATES, and ORC MACRO. Egypt service provision assessment survey 2004. Calverton, Maryland, Ministry of Health and Population and ORC Macro, 2005. 410 p.

64. MUTIHIR, J.T. (Jos University Teaching Hospital) [Implants pricing in Jos, Nigeria] Personal communication, Aug. 8, 2007.

*65. MUTIHIR, J.T., GUFUL, F., and UJAH, I.A. Norplant acceptors in Jos, Nigeria. Annals of African Medicine 5(1): 20-23. 2006.

66. NAKHAEE, N., MIRAHMADIZADEH, A.R., GORJI, H.A., and MOHAMMADI, M. Assessing the cost-effectiveness of contraceptive methods in Shiraz, Islamic Republic of Iran. Eastern Mediterranean Health Journal 8(1): 55-63. Jan. 2002.

67. ORGANON. Implanon® Clinician's Manual. 1999. 64 p.

*68. ORGANON. Implanon® Insertion, localization and removal techniques. CD-ROM. 2002.

*69. ORGANON. Implanon® Product Monograph. 2005. 84 p.

70. ORGANON. Implanon® Scientific Information. CD. 2005.

71. ORGANON. Implanon Launch. [brief]. 2006. 2 p. (unpublished)

72. ORGANON. Implanon® Guide de formation. CD-ROM. 2006.

73. ORGANON. Implanon: A special product for reaching the programmatic goals in family planning. [PowerPoint Presentation]. 2007.

*74. ORTAYLI, N. Users' perspectives on implantable contraceptives for women. Contraception 65(1): 107-111. Jan. 2002.

75. ORTAYLI, N. (World Health Organization) [WHO multi-site clinical trials to compare Implanon and Jadelle] Personal communication, Jun. 15, 2007.

76. ORTAYLI, N., AMCA, B., SAY, L., and BULUT, A. Acceptability of Norplant at a well-woman clinic in Turkey. European Journal of Contraception and Reproductive Health Care 5(2): 119-123. Jun. 2000.

77. PHILLIPS, C.J. Economic analysis of long-term reversible contraceptives. Focus on Implanon. Pharmacoeconomics 17(2): 209-221. Feb. 2000.

78. PILE, J. (EngenderHealth) [Contraceptive implants] Personal communication, Jun. 4, 2007.

79. PILE, J. (EngenderHealth) [EngenderHealth’s work to train providers in Ghana and Tanzania] Personal communication, Jul. 16, 2007.

*80. PILE, J., WILTSHIRE, J., KAKANDE, H., and SMITH, A. Recent trends in contraceptive prevalence and projections of contraceptive use: Implications for Uganda and ACQUIRE. [Unpublished powerpoint presentation, obtained through personal communication with John Pile and Alyson Smith.]. New York, EngenderHealth, The ACQUIRE Project, 24 p.

81. POINDEXTER, A. Contraceptive implants. [Online course]. Contraception Online, Mar. 2007.

*82. POWER, J., FRENCH, R., and COWAN, F. Subdermal implantable contraceptives versus other forms of reversible contraceptives or other implants as effective methods of preventing pregnancy. Cochrane Database of Systematic Review (3): CD001326. 2007.

83. PRAPTOHARDJO, U. and WIBOWO, S. The "U" technique: A new method for Norplant implants removal. Contraception 48(6): 526-536. Dec. 1993.

84. QUANSAH ASARE, G., KANLISI, N., JAIN, A., and PILE, J.M. Training nurses in Norplant® insertion/removal increases awareness of and access to Norplant® services in Ghana [poster]. Oct. 2006. Prepared for USAID's Global Mini-University, Washington, D.C.

85. RAO, R. and PANDIT, T. Nepal: Contraceptive security. Issues, findings, and recommendations. Arlington, Virginia, John Snow, Inc./DELIVER, for the U.S. Agency for International Development, Jan. 2004. 30 p.

*86. REPRODUCTIVE HEALTH SUPPLIES COALITION. RHInterchange. <http://rhi.rhsupplies.org/rhi/index.do> Accessed Jul. 5, 2007.

*87. RILLING, M. (U.S. Agency for International Development) [USAID Procurements of Implants] Personal communication, Jul. 23, 2007.

88. ROBERTS, D., PANITCHPAKDI, P., and LOEVINSOHN, B. Reducing discontinuation in family planning programs. Family Planning Manager 2(3): 1-24. May-Jun. 1993.

89. ROBEY, B., PIOTROW, P.T., and SALTER, C. Family planning lessons and challenges: Making programs work. Population Reports, Series J, No. 41. Baltmore, Johns Hopkins School of Public Health, Population Information Program, Aug. 1994.

90. ROIJMANS, F. (Organon) [Pricing of Implanon] Personal communication, Aug. 30, 2007.

91. SETTY-VENUGOPAL, V., JACOBY, R., and HART, C. Family planning logistics: Strengthening the supply chain. Population Reports, Series J, No. 51. Baltimore, The Johns Hopkins Bloomberg School of Public Health, Population Information Program, Winter 2002.

92. SIMMONS, R., FAJANS, P., and LUBIS, F. Contraceptive introduction and the management of choice: The role of Cyclofem in Indonesia. Contraception 49(5): 509-525. May 1994.

*93. SIMMONS, R., HALL, P., DIAZ, J., DIAZ, M., FAJANS, P., and SATIA, J. The strategic approach to contraceptive introduction. Studies in Family Planning 28(2): 79-94. Jun. 1997.

94. SIVIN, I. Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants. Drug Safety 26(5): 303-335. 2003.

*95. SIVIN, I., ALVAREZ, F., MISHELL, D.R., JR., DARNEY, P., WAN, L., BRACHE, V., LACARRA, M., KLAISLE, C., and STERN, J. Contraception with two levonorgestrel rod implants. A 5-year study in the United States and Dominican Republic. Contraception 58(5): 275-282. Nov. 1998.

*96. SIVIN, I., CAMPODONICO, I., KIRIWAT, O., HOLMA, P., DIAZ, S., WAN, L., BISWAS, A., VIEGAS, O., EL DIN ABDALLA, K., ANANT, M.P., PAVEZ, M., and STERN, J. The performance of levonorgestrel rod and Norplant contraceptive implants: A 5 year randomized study. Human Reproduction 13(12): 3371-3378. Dec. 1998.

*97. SIVIN, I., LAHTEENMAKI, P., RANTA, S., DARNEY, P., KLAISLE, C., WAN, L., MISHELL, D.R., JR., LACARRA, M., VIEGAS, O.A., BILHAREUS, P., KOETSAWANG, S., PIYA-ANANT, M., DIAZ, S., PAVEZ, M., ALVAREZ, F., BRACHE, V., LAGUARDIA, K., NASH, H., and STERN, J. Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants. Contraception 55(2): 81-85. Feb. 1997.

*98. SIVIN, I., MISHELL, D.R., JR., DIAZ, S., BISWAS, A., ALVAREZ, F., DARNEY, P., HOLMA, P., WAN, L., BRACHE, V., KIRIWAT, O., ABDALLA, K., CAMPODONICO, I., PASQUALE, S., PAVEZ, M., and SCHECHTER, J. Prolonged effectiveness of Norplant(R) capsule implants: a 7-year study. Contraception 61(3): 187-194. Mar. 2000.

*99. SIVIN, I., NASH, H., and WALDMAN, S. Jadelle® levonorgestrel rod implants: A summary of scientific data and lessons learned from programmatic experience. New York, Population Council, 2002. 48 p.

*100. SIVIN, I., VIEGAS, O., CAMPODONICO, I., DIAZ, S., PAVEZ, M., WAN, L., KOETSAWANG, S., KIRIWAT, O., ANANT, M.P., HOLMA, P., EL DIN ABDALLA, K., and STERN, J. Clinical performance of a new two-rod levonorgestrel contraceptive implant: A three-year randomized study with Norplant implants as controls. Contraception 55(2): 73-80. Feb. 1997.

101. SMITH, A. (EngenderHealth, The ACQUIRE Project) [Reality check] Personal communication, Jul. 5, 2006.

102. SMITH, A. and REUTER, S. An assessment of the use of Implanon in three community services. Journal of Family Planning and Reproductive Health Care 28(4): 193-196. Oct. 2002.

103. SOLO, J., ODONKOR, M., PILE, J., and WICKSTROM, J. Repositioning family planning—Ghana case study: ‘Give them the power.’ New York, The ACQUIRE Project/EngenderHealth, Sep. 2005. 38 p.

*104. SPICEHANDLER, J. and SIMMONS, R. Contraceptive introduction reconsidered: a review and conceptual framework. Geneva, World Health Organization, 1994.

*105. SPIELER, J. (United States Agency for International Development) [USAID purchasing of implants] Personal communication, Jun. 21, 2007.

106. STEINER, M. [International orders for implants] Personal communication, Aug. 24, 2007.

*107. STEINER, M.J. (Family Health International) [Sino-implant No. II Registrations in Africa] Personal communication, Jun.-Jul. 2007.

108. SULLIVAN, R.L. The competency-based approach to training. Baltimore, JHPIEGO, Sep. 1995. (JHPIEGO Strategy Paper No. 1) 9 p.

109. TAN, A., MAHDAR, E., DJAMAL, F.R., BACHTIAR, H., TULADHAR, J., and HOESNI, R.H. Improvements in knowledge of Norplant implants acceptors: An intervention study in West Sumatra and West Java, Indonesia. Final report. Bandung, Indonesia, Padjadjaran University, Study Group on Biomedical and Human Reproduction, Jun. 1995. 41 p.

110. THE ACQUIRE PROJECT. Reality √ family planning forecasting tool—a user's guide. [draft]. New York, The ACQUIRE Project, EngenderHealth, Aug. 2007. 2 p.

111. TOLLEY, E., LOZA, S., KAFAFI, L., and CUMMINGS, S. The impact of menstrual side effects on contraceptive discontinuation: Findings from a longitudinal study in Cairo, Egypt. International Family Planning Perspectives 31(1): 15-23. Mar. 2005.

112. TOLLEY, E. and NARE, C. Access to Norplant removal: An issue of informed choice. African Journal of Reproductive Health 5(1): 90-99. Apr. 2001.

113. TRUSSELL, J. Contraceptive efficacy. Hatcher, R., Trussell, J., Nelson, A., Cates Jr., W., Stewart, F., and Kowal, D. In: Contraceptive Technology. 19th revised ed. 2007 (in press)

114. UNFPA. UNFPA Procurement Statistics. 2006. 8 p.

115. UNITED NATIONS (UN). World contraceptive use 2005. [wall chart]. New York, Jan. 2006.

116. UNITED STATES DEPARTMENT OF STATE. Country reports on human rights practices: Ghana. 2003.

117. VARNEY, S.J. and GUEST, J.F. Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK. Pharmacoeconomics 22(17): 1141-1151. 2004.

118. VITZTHUM, V.J. and RINGHEIM, K. Hormonal contraception and physiology: A research-based theory of discontinuation due to side effects. Studies in Family Planning 36(1): 13-32. Mar. 2005.

119. WONDEMAGEGNEHU, E. Effective drug regulation: What can countries do? Geneva, World Health Organization, Mar. 1999. 53 p.

120. WORLD BANK GROUP. Health, nutrition, and population statistics: 2005 Demographic projections. World Bank Group, 2006.

*121. WORLD HEALTH ORGANIZATION (WHO). Medical eligibility criteria. WHO, 2004. 156 p.

*122. WORLD HEALTH ORGANIZATION (WHO). Selected practice recommendations for contraceptive use. 2nd ed. Geneva, WHO, Department of Reproductive Health and Research, 2004. 170 p.

123. WORLD HEALTH ORGANIZATION (WHO). WHO Model List of Essential Medicines. Mar. 2007. (15th edition)

*124. WORLD HEALTH ORGANIZATION DEPARTMENT OF REPRODUCTIVE HEALTH AND RESEARCH (WHO/RHR) and JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH/CENTER FOR COMMUNICATION PROGRAMS (CCP). Family planning: A global handbook for providers. Baltimore and Geneva, CCP and WHO, 2007.

*125. ZHENG, S.R., ZHENG, H.M., QIAN, S.Z., SANG, G.W., and KAPER, R.F. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception 60(1): 1-8. Jul. 1999.